Mirum plans $600 million convertible notes offering due 2032

Mirum Pharmaceuticals plans to raise $600 million through convertible senior notes due 2032, with an additional $90 million option for initial purchasers. Proceeds will partly fund exchanges of its 4.00% notes due 2029 and support general corporate purposes, including potential acquisitions. The financing follows strong Q1 2026 results, with revenue of $159.9 million beating estimates by 7.46%, though EPS missed sharply due to one-time acquisition-related expenses.

Analysis

This financing is less about balance-sheet survival and more about locking in cheap optionality while the equity is still near peak multiple. For existing holders, the overhang is not the cash raise itself but the mechanical supply created by delta-hedging and any forced unwind from holders of the 2029 convert; that can create a near-term technical bid in the stock even if fundamentals don’t change. The market should expect the cleanest trade to be in the next 1-3 sessions around pricing, not in the business story over the next quarter.

The bigger second-order effect is capital allocation optionality. Management is explicitly buying time to pursue tuck-in acquisitions, which signals confidence but also raises execution risk: in biotech, M&A done from a position of strength often destroys value when teams pay up for assets to justify a cash-rich story. If the new convert prices with only modest dilution, that is a tell that the street still assigns credible long-dated growth to the franchise; if it clears at a wide equity conversion premium, it suggests investors are already financing an outcome close to perfection.

Consensus is likely underestimating how asymmetric this setup is for volatility rather than direction. A convert deal near highs usually compresses future realized vol because it creates a supply-and-hedge cap, but it can also produce a sharp squeeze if the stock keeps drifting higher and dealers need to chase. The near-term downside is mostly event-driven and tactical; the medium-term risk is that any disappointment in growth or acquisition execution forces the stock to re-rate from “high-multiple growth” to “story stock with dilution,” which can be a fast 20-30% reset.

Key Decisions for Investors

• Short-dated hedge: buy MIRM puts or put spreads into pricing, 2-6 week tenor, targeting a post-deal supply flush; risk/reward is attractive if the stock fails to hold the pre-deal high.
• If you own MIRM, trim 20-30% into the convert announcement and replace with call spreads to keep upside participation while reducing dilution/supply risk over the next 1-2 months.
• Relative value: long MIRM / short a basket of slower-growth profitable biotech names only if the convert clears with a tight spread; otherwise avoid initiating until the financing technicals settle.
• Event-driven trade: look for a buy-the-dip entry only after pricing and 48-72 hours of digesting hedge-related flows; that is usually when the mechanical selling exhausts and fundamentals regain control.
• Avoid chasing upside before pricing; the best risk/reward is either hedged long or tactically short around the financing window, not outright long into the event.